The Evolution of Lymphangioleiomyomatosis (LAM) Management: From Hormonal Manipulation to Targeted Inhibition of the mammalian target of rapamycin (mTOR) Pathway. RSD [Internet]. 2025 Apr. 18 [cited 2025 Dec. 5];14(4):e4614448656. Available from: https://rsdjournal.org/rsd/article/view/48656